Arcutis Biotherapeutics, Inc.

This commercial-stage biopharmaceutical enterprise develops and markets treatments for immune-mediated skin disorders. The business concentrates on dermatological therapies, offering topical roflumilast formulations under the ZORYVE brand in cream and foam formats. These commercialized products are prescribed for conditions including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis across various adult and pediatric age groups. In addition to commercial assets, development efforts encompass an experimental biologic fusion protein, ARQ-234, aimed at inflammatory conditions. Target prescribers and healthcare customers primarily include dermatologists, pediatricians, and primary care physicians caring for patients with chronic inflammatory skin diseases.

Operations and commercial distribution are established in the United States and Canada, supplemented by international licensing and collaboration partnerships covering Japan, Greater China, and Southeast Asia. The provided filing text does not disclose the enterprise's corporate headquarters location or physical facility metrics.

Summary of the business section of Arcutis Biotherapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 354 full-time employees.”